lerisetron
Small moleculeexperimental
Lerisetron (code name F-0930-RS) is a drug which acts as an antagonist at the 5-HT3 receptor. It is a potent antiemetic and was in clinical trials for the treatment of nausea associated with cancer chemotherapy. — Wikipedia
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Jan 28, 2000 (NCT00004219)
Timeline
2000s
- Jan 1, 2000
Earliest Phase 3 Sponsor(trial)
Indications
Mechanism of action
- Serotonin 3a (5-HT3a) receptorINHIBITOR
HTR3A inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
c1ccc(Cn2c(N3CCNCC3)nc3ccccc32)cc1- Mol. weight
- 292.39 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaLerisetron ↗
- ChEMBLCHEMBL56900 ↗
Also known as
- 1-benzyl-2-(1-piperazinyl)benzimidazole
- lerisetron
- lerisetron
- lerisetron
- lerisetron
- lerisetron
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00004219 | Phase 3 | Jan 28, 2000 | Royal Marsden Hospital NHS Trust, Simbec-Orion |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Royal Marsden Hospital NHS Trust | Academic/Hospital | 1 | 0 | 1 | 2000 |
| Simbec-Orion | For profit | 1 | 1 | 1 | 2000 |
2 organizations
Page 1 / 1